Sir, I was disappointed to read the statement in an otherwise excellent document from the FGDP and College of General Dentistry that pre-treatment antiviral mouthwash was not recommended because of \'*a lack of evidence of virucidal activity for use of pre-operative mouthwash\'*. I wonder if a flurry of recent papers, possibly overlooked, might lead to a questioning of that statement. What is now known is that SARS-CoV-2 replicates in the oral cavity and that extremely high numbers (\>10 million) of infectious viral particles per ml saliva can be found at an early stage in SARS-CoV-2 infection.^[@CR21839]^ The virus in saliva is not contamination from elsewhere, but reflects active replication probably in ACE2 positive epithelial cells in minor salivary glands.^[@CR21846]^ Similar high levels are found in the nose.^[@CR21852]^

This is clearly an infection risk to any clinician working around the mouth or nose. Any virucidal agent applied to those sites may substantially reduce the risk of cross infection.^[@CR21858]^

Several commonly used antiseptic mouthwashes with anti-bacterial activity also have anti-viral activity against coronaviruses demonstrated *in vitro.*^[@CR21863]^ Two (povidone iodine and ethanol) have been shown to have substantial activity against SARS-CoV-2 and one (PVP-I) SARS-CoV in the presence of organic matter designed to replicate *in vivo* conditions.^[@CR21868]^ What is not known is how effective any anti-viral mouthwash actually is *in vivo*, nor how long the antiviral effect lasts. This has been estimated as greater than 20 minutes.^[@CR21858]^ Thus, does one recommend withholding a potentially effective agent (thus potentially exposing substantial numbers of dental HCWs to extra risk), or does one recommend that a simple, cheap, safe and potentially effective agent is used to help safeguard the profession while the extra information is sought?

PVP-I has been used in dentistry for over 60 years and its safety profile well established.^[@CR21858]^ Over 24 dental HCWs have now died with SARS-CoV-2. Anything which helps to keep the profession as safe as possible is surely to be supported.
